Hanmi Pharmaceutical Launches US Clinical Phase Ⅲ, the treatment for osteoarthritis
Hanmi Pharmaceutical Launches US Clinical Phase Ⅲ, the treatment for osteoarthritis
  • by Lee Jae-seung(jasonlee@koreaittimes.com)
  • 승인 2015.04.01 22:20
  • 댓글 0
이 기사를 공유합니다

Hanmi Pharmaceutical(www.hanmipharm.com) is launching the US clinical phase Ⅲ clinical trial on Hyalrheuma Injection for treatment of osteoarthritis.

On March 27, Hanmi(CEO&President. LEE, Gwansun) announced that Actavis, its trading partner received FDA approval of IDE (Investigational Device Exemption), the procedure of clinical test on medical device.

Hyalrheuma is a proven medicine in Korea, but it is classified as a medical device.

According to IDE approval, Actavis has a plan to evaluate the safety and effectiveness of the drug for fifteen months by injecting Hyalrheuma once a week for three weeks to 600 osteoarthritis patients in 50 U.S. institutions.

“Hyalrheuma Inj. is the first to be launched in the American market among Korean osteoarthritis treatment for inkection,” said an official from Hanmi, “We will make our best efforts to penetrate the market with Actavis.”

Meanwhile, Hanmi Pharmaceutical signed an agreement of $84 million export deal for twelve years with Actavis last July. Actavis, which was established in 1956, recorded its annual revenue of 10 trillion KRW, the No. 1 in the U.S. generic market.

By Lee Jae-seung

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.